

Merestinib

Catalog No: tcsc1192



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

1206799-15-6

Formula:

$C_{30}H_{22}F_2N_6O_3$

Pathway:

Protein Tyrosine Kinase/RTK

Target:

c-Met/HGFR

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 32 mg/mL (57.92 mM)

Alternative Names:

LY2801653

Observed Molecular Weight:

552.53


Product Description

Merestinib (LY2801653) is a type-II ATP competitive, slow-off inhibitor of **MET** tyrosine kinase with a dissociation constant (K_i) of 2 nM.

IC₅₀ & Target: Ki: 2 nM (c-Met)^[1]

In Vitro: Merestinib (LY2801653) demonstrates effects on MET pathway-dependent cell scattering and cell proliferation. The mean IC₅₀ value (n=6 determinations) of Merestinib (LY2801653) for inhibition of MET auto-phosphorylation in HGF-stimulated H460 cells is 35.2±6.9 nM and the IC₅₀ for MET auto-phosphorylation in S114 cells is 59.2 nM. Transfection with the MET variants confers growth-factor independence and treatment with Merestinib (LY2801653) inhibits growth of these MET variant clones with an IC₅₀ ranging from 3-fold more potent (V1092I) to approximately 6-fold less potent (L1195V) compare with the growth inhibition of cells with the MET wild-type sequence^[1]. Merestinib (LY2801653) (2, 5, and 10 μM) reduces the number of viable TFK-1 and SZ-1 cells in a dose and time dependent manner, and significant inhibits wound healing for TFK-1 and SZ-1 cell lines. Merestinib (LY2801653) inhibits cell invasion in TFK-1 and SZ-1 cells in a concentration dependent manner^[2].

In Vivo: Merestinib (LY2801653) demonstrates anti-tumor effects in MET amplified (MKN45), MET autocrine (U-87MG, and KP4) and MET over-expressed (H441) xenograft models; and in vivo vessel normalization effects. Merestinib (LY2801653) is a type-II ATP competitive, slow-off inhibitor of MET tyrosine kinase with a pharmacodynamic residence time (K_{off}) of 0.00132 min⁻¹ and $t_{1/2}$ of 525 min. Merestinib (LY2801653) treatment inhibits MET phosphorylation with a composite TED50 (50 % target inhibition dose) of 1.2 mg/kg and a composite TED90 (90 % target inhibition dose) of 7.4 mg/kg^[1]. Merestinib (LY2801653) (20 mg/kg) reduces TFK-1 tumor growth significantly relative to vehicle control. Merestinib (LY2801653) inhibits the growth of intra- and extrahepatic CCC xenograft tumors^[2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!